ERBB2 and neoplasm: In conclusion, this international large-scale pooled analysis shows that the effectiveness of first-line bevacizumab plus paclitaxel for HER2-negative MBC patients in routine clinical practice and identified independent prognostic factors, tumor subtype, age, ECOG PS, disease-free interval, liver metastasis, number of metastatic organs, and prior taxane and/or anthracycline use, in terms of OS.